prove to be considerably lower than suggested in the initial analysis, although still clinically important.
Third, tailoring individual medications in the context of combination therapy has less effect than might be expected, and an important role of polypills is improving long-term adherence to recommended combination therapy. After an individual medication is tailored to a patient, changes to the overall cardiovascular risk reduction conferred by all medications will be less marked than changes to the risk reduction conferred by that individual medication. To take the example cited by Dr Brugts, if the angiotensin-converting-enzyme (ACE) inhibitor genetic score data were judged to be reliable, the main clinical implication would be replacing ACE-inhibitor therapy in the subgroup of patients with a risk score >3 with another blood-pressure-lowering agent. The differences in predicted risk reduction from ACE-inhibitor therapy according to genetic risk score (Table 1) are extreme (from a 42% risk reduction in those with a risk score of 1 to an increase in risk of 26% in those with a risk score of 3, that is, a difference of 84 percentage points), but differences in overall cardiovascular risk reduction are much more modest (from a reduction of 70% in those with a risk score of 1 to a reduction of 36% in those with a risk score of 3, that is, a difference of 34 percentage points). In the context of additional therapies (such as dual antiplatelet therapy or potent statin therapy), the marginal benefits on overall risk reduction from tailoring individual therapy would be even more modest. Furthermore, at a population level, the effect on the total number of events prevented would not be high, because only 27% of the population have a genetic risk score ≥3. 3 Advances in tailoring treatment, such as the use of pharmacogenetic scores, might lead to improved blood-pressure control over time, although substantial barriers exist to implementing these strategies in everyday practice. Ensuring long-term adherence to combination therapy maximizes the likelihood of an acceptable overall cardiovascular risk reduction, helping to compensate for the inevitable, but usually undetectable, 4, 5 variations in a patient's response to individual drugs. 'Pharmacological autocompensation' is the technical term, but this phenomenon could just as easily be described as 'covering all your bases' or 'hedging your bets' . Although the potential to tailor individual medications to treat hypertension exists, only around half of patients with hypertension in high-income countries (and even fewer in low-income and middle-income countries) take any blood-pressure-lowering medication, and hypertension is controlled in only ~20% of these patients. 6 Ultimately, the most-important role for the polypill is to increase access and long-term adherence to combination therapy for the majority of people with cardiovascular disease globally, who receive few recommended medications or none at all. 
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